Stock PHAS.Q PHASEBIO PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials PhaseBio Pharmaceuticals, Inc.

Equities

PHAS.Q

US7172241090

Biotechnology & Medical Research

End-of-day quote OTC Markets
Other stock markets
 06:00:00 2024-06-26 pm EDT 		5-day change 1st Jan Change
0.000001 USD -.--% Intraday chart for PhaseBio Pharmaceuticals, Inc. -.--% -.--%
May. 13 Amended Disclosure Statement Conditionally Approved for PhaseBio Pharmaceuticals, Inc. CI
Apr. 19 First Amended Combined Liquidation Plan and Disclousre Statement Filed by PhaseBio Pharmaceuticals, Inc. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021
Capitalization 1 75.7 175.8 98.67 125.5
Enterprise Value (EV) 1 22.17 118.2 85.24 92.83
P/E ratio -0.69 x -4.28 x -0.99 x -0.87 x
Yield - - - -
Capitalization / Revenue 113,322,858 x 74,444,002 x 308,330,650 x 11,588,483 x
EV / Revenue 33,186,630 x 50,069,584 x 266,368,150 x 8,570,663 x
EV / EBITDA -1.13 x -2.99 x -1.01 x -0.88 x
EV / FCF -1,402,104 x -4,408,596 x -1,507,990 x -1,914,466 x
FCF Yield -0% -0% -0% -0%
Price to Book 1.49 x 2.93 x -3.93 x -1.35 x
Nbr of stocks (in thousands) 24,498 28,766 29,365 48,090
Reference price 2 3.090 6.110 3.360 2.610
Announcement Date 3/26/19 3/30/20 3/15/21 3/24/22
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net sales - - 0.668 2.361 0.32 10.83
EBITDA 1 -9.409 -8.442 -19.54 -39.56 -84.35 -105.6
EBIT 1 -9.501 -8.538 -19.64 -39.74 -84.86 -107.4
Operating Margin - - -2,940.72% -1,683.02% -26,517.5% -991.25%
Earnings before Tax (EBT) 1 -9.22 -10.25 -23.85 -39.25 -98.56 -129.5
Net income 1 -9.22 -10.25 -23.85 -39.25 -98.56 -131.1
Net margin - - -3,569.76% -1,662.3% -30,801.56% -1,210.15%
EPS 2 -12.41 -13.78 -4.495 -1.427 -3.392 -2.984
Free Cash Flow - -3.357 -15.81 -26.81 -56.52 -48.49
FCF margin - - -2,366.92% -1,135.73% -17,663.79% -447.68%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 9/21/18 9/21/18 3/26/19 3/30/20 3/15/21 3/24/22
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net Debt 1 - 2.08 - - - -
Net Cash position 1 3.72 - 53.5 57.5 13.4 32.7
Leverage (Debt/EBITDA) - -0.2458 x - - - -
Free Cash Flow - -3.36 -15.8 -26.8 -56.5 -48.5
ROE (net income / shareholders' equity) - 716% -106% -70.8% -567% 222%
ROA (Net income/ Total Assets) - -58.6% -31.8% -34.1% -79.8% -121%
Assets 1 - 17.49 74.9 115 123.5 108.3
Book Value Per Share 2 -117.0 -131.0 2.080 2.090 -0.8600 -1.930
Cash Flow per Share 2 5.000 18.00 2.490 2.570 0.9600 0.8700
Capex 1 0.09 0.22 0.12 0.96 1.31 2.68
Capex / Sales - - 17.81% 40.66% 410% 24.73%
Announcement Date 9/21/18 9/21/18 3/26/19 3/30/20 3/15/21 3/24/22
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PHASEBIO PHARMACEUTICALS, INC. Stock PhaseBio Pharmaceuticals, Inc.
-.--% 49
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.44% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+18.94% 113B
ARGENX SE Stock argenx SE
+18.22% 26.22B
BIONTECH SE Stock BioNTech SE
-25.37% 19.01B
GENMAB A/S Stock Genmab A/S
-19.84% 15.71B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.20% 15.22B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-47.37% 14.72B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+59.91% 14.58B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.35% 13.84B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PHAS.Q Stock
  4. Financials PhaseBio Pharmaceuticals, Inc.